Antifungal Resistance, Metabolic Routes as Drug Targets, and New Antifungal Agents: An Overview about Endemic Dimorphic Fungi

Imagem de Miniatura
Arquivos
art_PARENTE-ROCHA_Antifungal_Resistance_Metabolic_Routes_as_Drug_Targets_and_2017.PDF (1.47 MB)
Citações na Scopus
54
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HINDAWI LTD
Autores
PARENTE-ROCHA, Juliana Alves
BAILAO, Alexandre Melo
AMARAL, Andre Correa
PACCEZ, Juliano Domiraci
BORGES, Clayton Luiz
PEREIRA, Maristela
Citação
MEDIATORS OF INFLAMMATION, article ID 9870679, 16p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Diseases caused by fungi can occur in healthy people, but immunocompromised patients are the major risk group for invasive fungal infections. Cases of fungal resistance and the difficulty of treatment make fungal infections a public health problem. This review explores mechanisms used by fungi to promote fungal resistance, such as the mutation or overexpression of drug targets, efflux and degradation systems, and pleiotropic drug responses. Alternative novel drug targets have been investigated; these include metabolic routes used by fungi during infection, such as trehalose and amino acid metabolism and mitochondrial proteins. An overview of new antifungal agents, including nanostructured antifungals, as well as of repositioning approaches is discussed. Studies focusing on the development of vaccines against antifungal diseases have increased in recent years, as these strategies can be applied in combination with antifungal therapy to prevent posttreatment sequelae. Studies focused on the development of a pan-fungal vaccine and antifungal drugs can improve the treatment of immunocompromised patients and reduce treatment costs.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/21603
Referências
  1. Abe F, 2009, BBA-BIOMEMBRANES, V1788, P743, DOI 10.1016/j.bbamem.2008.12.002
  2. Almeida J. R., 2015, MED MYCOL, V53, P42
  3. Amaral AC, 2012, PEPTIDES, V37, P301, DOI 10.1016/j.peptides.2012.07.021
  4. Amaral AC, 2010, BRIT J PHARMACOL, V159, P1126, DOI 10.1111/j.1476-5381.2009.00617.x
  5. Amaral AC, 2009, J ANTIMICROB CHEMOTH, V63, P526, DOI 10.1093/jac/dkn539
  6. Amich J, 2016, CURR OPIN MICROBIOL, V32, P151, DOI 10.1016/j.mib.2016.06.003
  7. Anderson TM, 2014, NAT CHEM BIOL, V10, P400, DOI 10.1038/nchembio.1496
  8. Antoine N., 2015, VET MICROBIOL, V175, P304
  9. Araujo FS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004309
  10. Armstrong-James D, 2014, TRENDS MICROBIOL, V22, P120, DOI 10.1016/j.tim.2014.01.001
  11. Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
  12. Bailao AM, 2006, MICROBES INFECT, V8, P2686, DOI 10.1016/j.micinf.2006.07.019
  13. Baranska-Rybak W, 2006, J ANTIMICROB CHEMOTH, V57, P260, DOI 10.1093/jac/dki460
  14. Barelle CJ, 2006, CELL MICROBIOL, V8, P961, DOI 10.1111/j.1462-5822.2005.00676.x
  15. Bastos KP, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-29
  16. Batista VG, 2011, MYCOPATHOLOGIA, V172, P357, DOI 10.1007/s11046-011-9451-5
  17. Becker JM, 2010, P NATL ACAD SCI USA, V107, P22044, DOI 10.1073/pnas.1009845107
  18. Bernardino S, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002325
  19. Blum G, 2013, ANTIMICROB AGENTS CH, V57, P1583, DOI 10.1128/AAC.01283-12
  20. Brock M, 2009, CURR OPIN MICROBIOL, V12, P371, DOI 10.1016/j.mib.2009.05.004
  21. Bromley M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158724
  22. Brown GD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004404
  23. Buissa-Filho R, 2008, INFECT IMMUN, V76, P3321, DOI 10.1128/IAI.00349-08
  24. Burton MF, 2009, NAT PROD REP, V26, P1572, DOI 10.1039/b912533g
  25. Butts A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002870
  26. Calderone R, 2015, FEMS YEAST RES, V15, DOI 10.1093/femsyr/fov027
  27. Calderone R, 2014, FUTURE MICROBIOL, V9, P791, DOI [10.2217/fmb.14.32, 10.2217/FMB.14.32]
  28. Calich V. L. G., 2008, INNATE IMMUNITY PARA, P223
  29. Cao XF, 2015, EUR J MED CHEM, V102, P471, DOI 10.1016/j.ejmech.2015.08.023
  30. Mesa-Arango AC, 2014, ANTIMICROB AGENTS CH, V58, P6627, DOI 10.1128/AAC.03570-14
  31. Chandra J, 2001, J DENT RES, V80, P903
  32. Chaturvedi A. K., 2014, PLOS ONE, V9
  33. Chen CZ, 2011, ANTIMICROB AGENTS CH, V55, P667, DOI 10.1128/AAC.00618-10
  34. Chen K, 2013, ANNU REV IMMUNOL, V31, P605, DOI 10.1146/annurev-immunol-032712-100019
  35. Clemons KV, 2015, J MED MICROBIOL, V64, P1237, DOI 10.1099/jmm.0.000138
  36. Cole GT, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003768
  37. Costa M, 2007, MICROBIOL-SGM, V153, P4194, DOI 10.1099/mic.0.2007/009332-0
  38. Covian R, 2009, J BIOL CHEM, V284, P8605, DOI 10.1074/jbc.M808914200
  39. d'Angelo I, 2015, COLLOID SURFACE B, V135, P717, DOI 10.1016/j.colsurfb.2015.08.027
  40. d'Enfert C, 2009, CURR OPIN MICROBIOL, V12, P358, DOI 10.1016/j.mib.2009.05.008
  41. da Silva AR, 2016, ANTIMICROB AGENTS CH, V60, P3551, DOI 10.1128/AAC.01846-15
  42. de Mattos Grosso Daniela, 2003, Infection and Immunity, V71, P6534, DOI 10.1128/IAI.71.11.6534-6542.2003
  43. Deepe GS, 1996, J INFECT DIS, V174, P828
  44. Denning DW, 2003, LANCET, V362, P1142, DOI 10.1016/S0140-6736(03)14472-8
  45. Denning DW, 2002, J ANTIMICROB CHEMOTH, V49, P889, DOI 10.1093/jac/dkf045
  46. Denning DW, 1997, J ANTIMICROB CHEMOTH, V40, P611, DOI 10.1093/jac/40.5.611
  47. De Toledo L. G., 2016, INT J MOL SCI, V17
  48. Dijkgraaf GJP, 2002, YEAST, V19, P671, DOI 10.1002/yea.866
  49. Douglas L. Julia, 2002, Revista Iberoamericana de Micologia, V19, P139
  50. Elliott B, 1996, GENETICS, V144, P923
  51. Erjavec Z, 2002, DRUG RESIST UPDATE, V5, P3, DOI 10.1016/S1368-7646(02)00019-5
  52. Fan WH, 2005, EUKARYOT CELL, V4, P1420, DOI 10.1128/EC.4.8.1420-1433.2005
  53. Fekkar A, 2013, ANTIMICROB AGENTS CH, V57, P2380, DOI 10.1128/AAC.02037-12
  54. Feng YM, 2011, CAN J MICROBIOL, V57, P375, DOI 10.1139/W11-023
  55. Fernandes VC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017885
  56. de Almeida JRF, 2015, MED MYCOL, V53, P42, DOI 10.1093/mmy/myu049
  57. Forastiero A, 2013, ANTIMICROB AGENTS CH, V57, P4769, DOI 10.1128/AAC.00477-13
  58. Fradin C, 2005, MOL MICROBIOL, V56, P397, DOI 10.1111/j.1365-2958.2005.04557.x
  59. Garcia R, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1879-4
  60. Garcia-Effron G, 2009, ANTIMICROB AGENTS CH, V53, P3690, DOI 10.1128/AAC.00443-09
  61. Garcia-Effron G, 2009, ANTIMICROB AGENTS CH, V53, P112, DOI 10.1128/AAC.01162-08
  62. Gardiner RE, 2005, MED MYCOL, V43, pS299, DOI 10.1080/13693780400029023
  63. Garfoot AL, 2014, INFECT IMMUN, V82, P393, DOI 10.1128/IAI.00824-13
  64. Garnaud C, 2015, J ANTIMICROB CHEMOTH, V70, P2556, DOI 10.1093/jac/dkv139
  65. Godfrey DI, 2010, NAT IMMUNOL, V11, P197, DOI 10.1038/ni.1841
  66. Goughenour KD, 2017, VIRULENCE, V8, P211, DOI 10.1080/21505594.2016.1235653
  67. Grahl N, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005133
  68. Gruszecki WI, 2003, CELL MOL BIOL LETT, V8, P161
  69. Gsaller F, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005775
  70. Guirao-Abad JP, 2013, INT MICROBIOL, V16, P217
  71. Gutierrez-Cirlos EB, 2004, J BIOL CHEM, V279, P8708, DOI 10.1074/jbc.M311805200
  72. Hagiwara D, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01382
  73. HAMILTONMILLER JM, 1973, BACTERIOL REV, V37, P166
  74. Han J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150196
  75. Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267
  76. Hayes BME, 2013, ANTIMICROB AGENTS CH, V57, P3667, DOI 10.1128/AAC.00365-13
  77. Hein KZ, 2015, P NATL ACAD SCI USA, V112, P13039, DOI 10.1073/pnas.1511197112
  78. Hemmati S, 2016, MOLECULES, V21, DOI 10.3390/molecules21070820
  79. Hensel M, 1998, MOL GEN GENET, V258, P553
  80. Hoekstra WJ, 2014, BIOORG MED CHEM LETT, V24, P3455, DOI 10.1016/j.bmcl.2014.05.068
  81. Hsieh SH, 2011, INFECT IMMUN, V79, P4493, DOI 10.1128/IAI.05350-11
  82. Huang RL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001862
  83. Hung CY, 2012, VACCINE, V30, P4681, DOI 10.1016/j.vaccine.2012.04.084
  84. Hurtgen BJ, 2012, INFECT IMMUN, V80, P3960, DOI 10.1128/IAI.00566-12
  85. Ibrahim-Granet O, 2008, CELL MICROBIOL, V10, P134, DOI 10.1111/j.1462-5822.2007.01025.x
  86. Ishihara S, 2007, EUKARYOT CELL, V6, P143, DOI 10.1128/EC.00200-06
  87. Jampilek J, 2016, FUTURE MED CHEM, V8, P1393, DOI 10.4155/fmc-2016-0124
  88. Jensen RH, 2013, ANTIMICROB AGENTS CH, V57, P614, DOI 10.1128/AAC.01193-12
  89. Johnson SM, 2007, ANN NY ACAD SCI, V1111, P290, DOI 10.1196/annals.1406.042
  90. Katiyar S, 2006, ANTIMICROB AGENTS CH, V50, P2892, DOI 10.1128/AAC.00349-06
  91. Katiyar SK, 2012, ANTIMICROB AGENTS CH, V56, P6304, DOI 10.1128/AAC.00813-12
  92. Katiyar SK, 2009, ANTIMICROB AGENTS CH, V53, P1772, DOI 10.1128/AAC.00020-09
  93. Katragkou A, 2016, EXPERT OPIN PHARMACO, V17, P1179, DOI 10.1080/14656566.2016.1186647
  94. Kingsbury JM, 2008, MICROBIOL-SGM, V154, P2767, DOI 10.1099/mic.0.2008/019729-0
  95. Koselny K, 2016, ANTIMICROB AGENTS CH, V60, P7115, DOI 10.1128/AAC.01061-16
  96. Krappmann S, 2004, MOL MICROBIOL, V52, P785, DOI 10.1111/j.1365-2958.2004.04015.x
  97. Laniado-Laborin R, 2009, REV IBEROAM MICOL, V26, P223, DOI 10.1016/j.riam.2009.06.003
  98. Levitz SM, 2017, MED MYCOL, V55, P103, DOI 10.1093/mmy/myw081
  99. Li DM, 2016, CURR GENET, V62, P87, DOI 10.1007/s00294-015-0518-6
  100. LILLIE SH, 1980, J BACTERIOL, V143, P1384
  101. Fontes ACL, 2017, MED MYCOL, V55, P203, DOI 10.1093/mmy/myw056
  102. Liu LH, 2013, NANOSCALE, V5, P3834, DOI 10.1039/c3nr34254a
  103. Longhi LNA, 2012, J IMMUNOL, V189, P935, DOI 10.4049/jimmunol.1102563
  104. Lopez-Abarrategui C, 2015, FASEB J, V29, P3315, DOI 10.1096/fj.14-269860
  105. Lorenz MC, 2004, EUKARYOT CELL, V3, P1076, DOI 10.1128/EC.3.5.1075-1087.2004
  106. Low Chian-Yong, 2011, F1000 Med Rep, V3, P14, DOI 10.3410/M3-14
  107. Marques AF, 2008, MICROBES INFECT, V10, P1251, DOI 10.1016/j.micinf.2008.07.027
  108. Martins EMDN, 2007, VACCINE, V25, P7893, DOI 10.1016/j.vaccine.2007.09.011
  109. Mayorga O., 2012, FRONTIERS MICROBIOLO, V3, P1
  110. Medici NP, 2015, MEM I OSWALDO CRUZ, V110, P966, DOI 10.1590/0074-02760150335
  111. Moffa EB, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00885
  112. Moghadamtousi SZ, 2014, BIOMED RES INT, DOI 10.1155/2014/186864
  113. Moniruzzaman M, 2015, BIOCHEMISTRY-US, V54, P5802, DOI 10.1021/acs.biochem.5b00594
  114. Munoz JF, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005493
  115. Nanjappa SG, 2014, CURR OPIN IMMUNOL, V28, P27, DOI 10.1016/j.coi.2014.01.014
  116. Nanjappa SG, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002771
  117. Neubauer M, 2015, MOL MICROBIOL, V98, P930, DOI 10.1111/mmi.13167
  118. Ngamskulrungroj P, 2009, INFECT IMMUN, V77, P4584, DOI 10.1128/IAI.00565-09
  119. Oguro Y, 2014, CURR GENET, V60, P89, DOI 10.1007/s00294-013-0416-8
  120. Oliver JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043559
  121. Omrane S, 2015, ENVIRON MICROBIOL, V17, P2805, DOI 10.1111/1462-2920.12781
  122. Osherov N, 2017, MED MYCOL, V55, P118, DOI 10.1093/mmy/myw060
  123. Pal I, 2016, J COLLOID INTERF SCI, V483, P385, DOI 10.1016/j.jcis.2016.08.043
  124. Parente AFA, 2015, MICROBES INFECT, V17, P575, DOI 10.1016/j.micinf.2015.03.012
  125. Pasquale T, 2008, J ANTIMICROB CHEMOTH, V61, P219, DOI 10.1093/jac/dkm453
  126. Paul S, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00143
  127. Pedreno Y, 2007, MICROBIOL-SGM, V153, P1372, DOI 10.1099/mic.0.2006/003921-0
  128. Perfect JR, 2017, VIRULENCE, V8, P143, DOI 10.1080/21505594.2016.1195529
  129. Perlin DS, 2015, ANN NY ACAD SCI, V1354, P1, DOI 10.1111/nyas.12831
  130. Perlin DS, 2011, FUTURE MICROBIOL, V6, P441, DOI [10.2217/fmb.11.19, 10.2217/FMB.11.19]
  131. Petzold EW, 2006, INFECT IMMUN, V74, P5877, DOI 10.1128/IAI.00624-06
  132. Pfaller MA, 2012, AM J MED, V125, pS3, DOI 10.1016/j.amjmed.2011.11.001
  133. Pham CD, 2014, ANTIMICROB AGENTS CH, V58, P4690, DOI 10.1128/AAC.03255-14
  134. Pianalto K. M., 2016, J FUNGI, V2
  135. Pietrella D, 2010, VACCINE, V28, P1717, DOI 10.1016/j.vaccine.2009.12.021
  136. Piras AM, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00372
  137. Portuondo DL, 2016, IMMUNOBIOLOGY, V221, P300, DOI 10.1016/j.imbio.2015.10.005
  138. Prado RS, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00616
  139. Rajendran R, 2016, CLIN MICROBIOL INFEC, V22, P87, DOI 10.1016/j.cmi.2015.09.018
  140. Rapala-Kozik M, 2015, INFECT IMMUN, V83, P2518, DOI 10.1128/IAI.00023-15
  141. Ren TB, 2009, J BIOMAT SCI-POLYM E, V20, P1369, DOI [10.1163/092050609X12457418779185, 10.1163/0920506O9X12457418779185]
  142. Rezende TCV, 2011, J PROTEOMICS, V75, P572, DOI 10.1016/j.jprot.2011.08.020
  143. Rippon J. W., 1988, MED MYCOLOGY PATHOGE
  144. Robbins N, 2015, CELL REP, V13, P1481, DOI 10.1016/j.celrep.2015.10.018
  145. Abadio AKR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142926
  146. Roemer T, 2014, COLD SPRING HARB PER, V4
  147. Roemer T, 2013, NAT CHEM BIOL, V9, P222, DOI [10.1038/nchembio.1205, 10.1038/NCHEMBIO.1205]
  148. Roemer T, 2012, NAT CHEM BIOL, V8, P46, DOI 10.1038/nchembio.744
  149. Roemer T, 2011, CHEM BIOL, V18, P148, DOI 10.1016/j.chembiol.2011.01.009
  150. Roussey J. A., 2016, MICROORGANISMS, V4
  151. Rude TH, 2002, INFECT IMMUN, V70, P5684, DOI 10.1128/IAI.70.10.5684-5694.2002
  152. Samuelson DR, 2016, J IMMUNOL, V196, P2655, DOI 10.4049/jimmunol.1502004
  153. Sanchez-Fresneda R, 2009, BIOCHEM BIOPH RES CO, V383, P98, DOI 10.1016/j.bbrc.2009.03.134
  154. Sasse A, 2016, VIRULENCE, V7, P56, DOI 10.1080/21505594.2015.1109766
  155. Scarsini M, 2015, PEPTIDES, V71, P211, DOI 10.1016/j.peptides.2015.07.023
  156. Schobel F, 2007, INFECT IMMUN, V75, P1237, DOI 10.1128/IAI.01416-06
  157. Schobel F, 2010, EUKARYOT CELL, V9, P878, DOI 10.1128/EC.00020-10
  158. Seleem D, 2016, PEERJ, V4, DOI 10.7717/peerj.2148
  159. Seleem D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157188
  160. She XD, 2015, CELL MICROBIOL, V17, P1350, DOI 10.1111/cmi.12438
  161. Shen MQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057667
  162. Shi W, 2016, BIOORG MED CHEM LETT, V26, P2156, DOI 10.1016/j.bmcl.2016.03.073
  163. Shields RK, 2015, ANTIMICROB AGENTS CH, V59, P7465, DOI 10.1128/AAC.01973-15
  164. Shubitz LF, 2015, ANTIMICROB AGENTS CH, V59, P7249, DOI 10.1128/AAC.00593-15
  165. Singer MA, 1998, TRENDS BIOTECHNOL, V16, P460, DOI 10.1016/S0167-7799(98)01251-7
  166. Singh SB, 2013, BIOORG MED CHEM LETT, V23, P3018, DOI 10.1016/j.bmcl.2013.03.023
  167. Snelders E, 2011, FUNGAL GENET BIOL, V48, P1062, DOI 10.1016/j.fgb.2011.08.002
  168. Souza ACO, 2015, EUR J MED CHEM, V95, P267, DOI 10.1016/j.ejmech.2015.03.022
  169. Staniszewska M, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01309
  170. Stevens DA, 2011, MED MYCOL, V49, pS170, DOI 10.3109/13693786.2010.497775
  171. Sun W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070506
  172. Taborda CP, 2015, REV INST MED TROP SP, V57, P21, DOI 10.1590/S0036-46652015000700005
  173. Taborda CP, 2003, J IMMUNOL, V170, P3621
  174. Taborda CP, 2002, IMMUNITY, V16, P791, DOI 10.1016/S1074-7613(02)00328-X
  175. Tene N, 2016, PEPTIDES, V79, P103, DOI 10.1016/j.peptides.2016.04.001
  176. Thomaz L, 2014, MICROBES INFECT, V16, P788, DOI 10.1016/j.micinf.2014.08.004
  177. Thompson GR, 2008, ANTIMICROB AGENTS CH, V52, P3783, DOI 10.1128/AAC.00473-08
  178. Torosantucci A, 2005, J EXP MED, V202, P597, DOI 10.1084/jem.20050749
  179. Travassos LR, 2008, MYCOPATHOLOGIA, V165, P341, DOI 10.1007/s11046-007-9056-1
  180. Travassos LR, 2008, EXPERT REV ANTI-INFE, V6, P251, DOI 10.1586/14787210.6.2.251
  181. Ueno K, 2011, FEMS YEAST RES, V11, P398, DOI 10.1111/j.1567-1364.2011.00728.x
  182. Vincent BM, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001692
  183. Walker LA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000040
  184. Walker LA, 2013, ANTIMICROB AGENTS CH, V57, P146, DOI 10.1128/AAC.01486-12
  185. Wang HF, 2016, INFECT IMMUN, V84, P635, DOI 10.1128/IAI.01263-15
  186. Wang XJ, 2015, VIRULENCE, V6, P309, DOI 10.4161/21505594.2014.983015
  187. Wanke B, 2000, MEM I OSWALDO CRUZ, V95, P153, DOI 10.1590/S0074-02762000000700025
  188. Warrilow AGS, 2014, ANTIMICROB AGENTS CH, V58, P7121, DOI 10.1128/AAC.03707-14
  189. Wheat LJ, 2001, CLIN INFECT DIS, V33, P1910, DOI 10.1086/323781
  190. White TC, 1998, CLIN MICROBIOL REV, V11, P382
  191. Wong LP, 2002, VACCINE, V20, P2878, DOI 10.1016/S0264-410X(02)00234-7
  192. Wuthrich M, 2015, CELL HOST MICROBE, V17, P452, DOI 10.1016/j.chom.2015.02.009
  193. Wuthrich M, 2012, ANNU REV IMMUNOL, V30, P115, DOI 10.1146/annurev-immunol-020711-074958
  194. Wuthrich M, 2011, CLIN VACCINE IMMUNOL, V18, P783, DOI 10.1128/CVI.00560-10
  195. Wuthrich M, 2011, J CLIN INVEST, V121, P554, DOI 10.1172/JCI43984
  196. Xu N, 2011, INT J NANOMED, V6, P905, DOI 10.2147/IJN.S17503
  197. Yibmantasiri P, 2014, MOL BIOSYST, V10, P128, DOI 10.1039/c3mb70351g
  198. Zerbini LF, 2014, MOL CANCER THER, V13, P1929, DOI 10.1158/1535-7163.MCT-13-0750

Coleções
Artigos e Materiais de Revistas Científicas - LIM/53